Online inquiry

IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8092MR)

This product GTTS-WQ8092MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Dermatomyositis, Nephritis, Atypical hemolytic uremic syndrome (aHUS) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, h5G1.1HuG2/G4(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ8092MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12625MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ1647MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACT-017
GTTS-WQ6305MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CS-1008
GTTS-WQ9738MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JR-141
GTTS-WQ13936MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-2810
GTTS-WQ12252MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MRA
GTTS-WQ10936MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ5315MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD20-TCB (2:1)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW